Wyndham Reports Q4 Net Loss Due to Impairment, Full-Year Adjusted EPS Growth, and Raises Dividend

summarizeSummary

Wyndham Hotels & Resorts reported a Q4 2025 net loss and lower full-year reported net income due to significant impairment charges related to a European franchisee's insolvency, but highlighted full-year adjusted EPS growth, a record development pipeline, and a 5% dividend increase.

check_boxKey Events

• Q4 and Full-Year 2025 Financial Results

  The company reported a Q4 2025 net loss of $60 million and full-year net income of $193 million, a 33% decrease from 2024, primarily due to impairment charges. However, full-year adjusted diluted EPS increased 6% to $4.58, and adjusted EBITDA grew 4% on a comparable basis to $718 million, aligning with expectations.

• Significant Impairment Charges

  Wyndham recorded $160 million in non-cash impairment and other-related charges in Q4 2025. This includes $74 million in operating expenses, $48 million in impairment, and $38 million for the Vienna House trademark, all linked to the insolvency of European franchisee Revo Hospitality Group.

• Increased Dividend and Shareholder Returns

  The Board of Directors authorized a 5% increase in the quarterly cash dividend to $0.43 per share, starting in Q1 2026. For the full-year 2025, the company returned $393 million to shareholders through $266 million in share repurchases and $127 million in cash dividends.

• Strong Development Pipeline and Room Growth

  System-wide rooms grew 4% year-over-year, with a record 870 development contracts awarded globally in 2025 (up 18%). The global development pipeline reached a record 259,000 rooms, growing 3% year-over-year.

auto_awesomeAnalysis

Wyndham Hotels & Resorts reported a net loss for Q4 2025 and a significant decrease in full-year reported net income, primarily driven by substantial non-cash impairment and other-related charges totaling $160 million. These charges stem from the insolvency proceedings of a large European franchisee, Revo Hospitality Group, and related trademark impairment. Despite these reported GAAP losses, the company demonstrated underlying operational strength with full-year 2025 adjusted diluted EPS increasing 6% and adjusted EBITDA growing 4% on a comparable basis, meeting expectations. The company also returned $393 million to shareholders through share repurchases and dividends, and authorized a 5% increase in its quarterly cash dividend. The 2026 outlook projects continued room growth and adjusted EBITDA/EPS growth, though global RevPAR is expected to be flat to slightly negative. Investors should differentiate between the one-time non-cash impairment impact on reported earnings and the positive trends in adjusted financial metrics and development pipeline.